In 2022, Chintu Patel earned $950.00K in total compensation at Amneal Pharmaceuticals, Inc., including $500.00K salary, $100.00K bonus and $300.00K in stock. Most recently acquired 150,000 shares in Dec 2021. Currently holds stock worth $613.51M. Led Amneal Pharmaceuticals, Inc. as CEO for 2 years.
Compensation History
Annual executive compensation data for Chintu Patel, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$950.00K
Salary
$500.00K
Bonus
$100.00K
Other
$50.00K
Salary
$500.00KBoard Justification
The compensation philosophy is designed to align CEO compensation with company performance, market competitiveness, and retention strategies.
Bonus
$100.00KBoard Justification
The bonus is based on the company's performance metrics including revenue growth and EBITDA targets for the fiscal year 2022.
Other Compensation
$50.00KBoard Justification
Other compensation includes health benefits, retirement contributions, and perquisites.
Restricted Stock
Board Justification
The stock that vested in 2022 was part of a long-term incentive plan based on performance metrics over a three-year period.
Performance Metrics
Performance metrics include revenue growth, EBITDA targets, and total shareholder return.
Chintu Patel
Founder and Ex-CEO of Amneal Pharmaceuticals, Inc.
Education
Bachelor's degree in pharmacy from Rutgers College of Pharmacy.
Sector of Economy
Healthcare
Born
January 1, 1974 - 51 years ago
CEO of Amneal Pharmaceuticals, Inc. for
2 years 7 months (Aug 2019 - Mar 2022)
Previous Experience
Co-Founder of Amneal Pharmaceuticals, LLC and served as Co-Chairman and Co-Chief Executive Officer from 2002 to 2017.
Other Amneal Pharmaceuticals, Inc. CEOs
Holdings
Track Chintu Patel's stock holdings and portfolio value over time.
Insider Trading
Chintu Patel's recent stock transactions, purchases, and sales filed with the SEC.
$628.50K
AMRX at $4.19/share
Dec 15, 2021
Purchase
$309.00K
AMRX at $3.09/share
Mar 10, 2020
Purchase
$976.67K
AMRX at $3.91/share
Mar 2, 2020
Purchase
Rivals
Compare Chintu Patel with competitor CEOs and industry peers.